A landmark study reveals that independent clinical experts are far more likely to approve healthcare coverage than insurance companies themselves. Between 2019 and 2025, independent review organizations in New York State overturned nearly 50% of denied health insurance claims when patients appealed. Even more striking, the data shows that persistence pays off: nearly 80% of all appealed cases resulted in the reversal of the initial denial.
This finding, published in JAMA Internal Medicine, underscores a critical tension in the modern healthcare system. While insurers argue that “prior authorization” (pre-approval for treatments) ensures medical necessity and controls costs, the high rate of overturned denials suggests these processes often block appropriate care without saving money. The data raises urgent questions about whether current administrative barriers are harming patient outcomes and driving up long-term costs.
The Burden of Prior Authorization
Prior authorization requires doctors and patients to obtain pre-approval from insurers before receiving specific treatments, particularly for brand-name drugs with generic alternatives or high-cost therapies. From an insurer’s perspective, this is a safeguard against unnecessary spending. However, the reality for patients is often a bureaucratic maze.
Millions of claim denials occur annually across both commercial and public insurance markets. The process is frequently described as cumbersome and time-consuming. As reported by NBC News, many patients find themselves stuck in “prior authorization purgatory,” running out of time or viable treatment options while waiting for approval.
The problem is not limited to private insurers. A 2022 memorandum from the Office of Inspector General highlighted instances where Medicare Advantage plans incorrectly denied services to beneficiaries who clearly met coverage rules. This suggests that the administrative machinery often fails to align with actual clinical guidelines.
AI and the New Wave of Restrictions
The debate over prior authorization has intensified with the introduction of artificial intelligence (AI) in care management. Under the Trump administration, the Centers for Medicare and Medicaid Services (CMS) launched a demonstration project called WISeR (Wasteful and Inappropriate Service Reduction). This initiative contracts private, for-profit entities to use AI to assess the necessity of care for seniors enrolled in Medicare Advantage plans.
Critics, including former Cigna executive Wendell Potter, argue that this model is flawed. Early investigations indicate that the WISeR pilot in six states has led to delays in care and increased denials.
While traditional Medicare uses prior authorization sparingly—restricting it to only 52 outpatient services and specific equipment—Medicare Advantage insurers have deployed it extensively, subjecting hundreds of procedures to utilization restrictions. This disparity creates a two-tiered system where the complexity of accessing care depends heavily on the type of insurance plan a senior holds.
Industry Promises vs. Regulatory Pressure
Facing mounting criticism, major health insurers have pledged to reform their practices. Last summer, representatives from several large plans promised the Department of Health and Human Services (HHS) that they would:
- Reduce the number of claims subject to prior authorization.
- Standardize electronic requests for exemptions and appeals.
- Resolve 90% of requests in real time by 2027.
Insurers have expressed hope that improved AI technology will facilitate more efficient, “patient-friendly” decision-making. However, skepticism remains. When asked in 2025 why he believed the industry could succeed where others had failed, CMS Administrator Mehmet Oz stated, “Either you fix it, or we’ll fix it,” signaling that the administration is prepared to enforce regulatory changes if voluntary reforms fail.
This threat is backed by bipartisan legislative efforts aimed at standardizing prior authorization procedures, increasing transparency, and mandating clear timelines for appeals. Lawmakers are pushing for insurers to provide detailed clinical reasoning for every denial, a move designed to shift the power dynamic toward patients and providers.
The Economic and Clinical Case for Reform
The argument against current prior authorization practices is not just about convenience; it is about efficacy and cost. Decades ago, prior authorization was introduced to ensure patient safety—such as checking for drug interactions or confirming biomarker compatibility. While these valid safety checks remain necessary, the tool has evolved into a broad financial gatekeeping mechanism.
The data suggests this approach may be counterproductive:
* Administrative Burden: The process increases workload for doctors and delays care for patients.
* Worse Health Outcomes: Delays can lead to disease progression, resulting in higher long-term costs.
* Minimal Savings: If insurers deny care that is later deemed necessary upon appeal, they do not save money. In 2021, 82% of 35 million prior authorization requests to Medicare Advantage plans were reversed after appeal.
As noted by policy experts at the Center for American Progress, the current system often results in delays and outright denials of necessary care. They propose replacing standard prior authorization protocols with independent clinical reviews. In this model, coverage decisions would be based solely on evidence-based medical criteria reviewed by clinicians unaffiliated with the insurer.
Conclusion
The high rate of overturned denials in New York demonstrates that independent clinical judgment is more accurate than insurer-led administrative reviews. While prior authorization has a legitimate role in ensuring safety, its current implementation often obstructs care without delivering significant financial benefits. Moving toward a system of independent, evidence-based reviews could reduce administrative waste, improve patient outcomes, and create a more equitable healthcare environment.
